HORSKÁ, Kateřina, Jana RUDÁ, Michal KARPISEK, Radka OPATŘILOVÁ, Pavel SUCHÝ and Hana KOTOLOVÁ. Depot risperidone-induced adverse metabolic alterations in female rats. Journal of Psychopharmacology. London: SAGE Publications Ltd., 2017, vol. 31, No 4, p. 487-499. ISSN 0269-8811. Available from: https://dx.doi.org/10.1177/0269881117691466.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Depot risperidone-induced adverse metabolic alterations in female rats
Authors HORSKÁ, Kateřina (203 Czech Republic), Jana RUDÁ (203 Czech Republic, guarantor, belonging to the institution), Michal KARPISEK (203 Czech Republic), Radka OPATŘILOVÁ (203 Czech Republic), Pavel SUCHÝ (203 Czech Republic) and Hana KOTOLOVÁ (203 Czech Republic).
Edition Journal of Psychopharmacology, London, SAGE Publications Ltd. 2017, 0269-8811.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30104 Pharmacology and pharmacy
Country of publisher United Kingdom of Great Britain and Northern Ireland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 4.738
RIV identification code RIV/00216224:14110/17:00096183
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1177/0269881117691466
UT WoS 000400179400009
Keywords in English Adipokine; depot risperidone; leptin; lipid profile; Sprague-Dawley rats
Tags EL OK
Tags International impact, Reviewed
Changed by Changed by: Ing. Marcela Sedlářová, učo 402191. Changed: 14/1/2021 13:51.
Abstract
Atypical antipsychotics are associated with adverse metabolic effects including weight gain, increased adiposity, dyslipidaemia, alterations in glucose metabolism and insulin resistance. Increasing evidence suggests that metabolic dysregulation precedes weight gain development. The aim of this study was to evaluate alterations in adipokines, hormones and basic serum biochemical parameters induced by chronic treatment with depot risperidone at two doses (20 and 40 mg/kg) in female Sprague–Dawley rats. Dose-dependent metabolic alterations induced by risperidone after 6 weeks of treatment were revealed. Concomitant to weight gain and increased liver weight, an adverse lipid profile with an elevated triglyceride level was observed in the high exposure group, administered a 40 mg/kg dose repeatedly, while the low dose exposure group, administered a 20 mg/kg dose, developed weight gain without alterations in the lipid profile and adipokine levels. An initial peak in leptin serum level after the higher dose was observed in the absence of weight gain. This finding may indicate that the metabolic alterations observed in this study are not consequent to body weight gain. Taken together, these data may support the primary effects of atypical antipsychotics on peripheral tissues.
Links
ROZV/24/LF/2016, interní kód MUName: LF - Příspěvek IP 2016
Investor: Ministry of Education, Youth and Sports of the CR
PrintDisplayed: 27/4/2024 02:08